ASSOCIATION FOR ACCESSIBLE MEDICINES — Lobbying Disclosure | Poliscope

ASSOCIATION FOR ACCESSIBLE MEDICINES

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$64.6M

Filings

191

Firms Hired

Active Period

1999–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$2,480,000	14	5
2025	$3,090,000	20	5
2024	$2,950,000	9	2
2023	$2,030,000	8	2
2022	$3,190,000	8	2
2021	$2,840,000	9	3
2020	$3,990,000	12	3
2019	$4,750,000	15	4
2018	$7,010,000	20	4
2017	$4,170,000	14	3
2016	$6,289,533	16	3
2015	$3,320,000	4	1
2014	$3,426,566	5	1
2013	$2,220,305	4	1
2012	$1,959,462	4	1
2011	$2,082,372	4	1
2010	$1,858,142	4	1
2009	$2,178,807	4	1
2008	$1,940,244	4	1
2007	$818,128	2	1
2006	$311,000	1	1
2005	$299,928	1	1
2003	$240,000	1	1
2002	$360,000	2	1
2001	$260,000	2	1
2000	$340,000	3	1
1999	$180,000	1	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
ASSOCIATION FOR ACCESSIBLE MEDICINES	$64,584,487	100
THE GIBSON GROUP, LLC	—	42
QUADRIPOINT STRATEGIES LLC	—	16
RUBIN, TURNBULL & ASSOCIATES	—	5
FOLEY & LARDNER LLP	—	8
POLARIS GOVERNMENT RELATIONS, LLC	—	11
SQUIRE PATTON BOGGS	—	7
WILEY REIN LLP	—	2

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	155
SENATE	138
Centers For Medicare and Medicaid Services (CMS)	75
Health & Human Services, Dept of (HHS)	74
Food & Drug Administration (FDA)	73
White House Office	72
U.S. Trade Representative (USTR)	67
Commerce, Dept of (DOC)	47
Federal Trade Commission (FTC)	46
Congressional Budget Office (CBO)	39
Office of Management & Budget (OMB)	38
Natl Economic Council (NEC)	25
Patent & Trademark Office (PTO)	23
Office of the Vice President of the United States	17
Government Accountability Office (GAO)	13
Medicare Payment Advisory Commission (MedPAC)	7
State, Dept of (DOS)	6
U.S. Customs & Border Protection	5
Drug Enforcement Administration (DEA)	4
Treasury, Dept of	4

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Pharmacy	Pharmacy	141
Trade (domestic/foreign)	Trade (domestic/foreign)	132
Copyright/Patent/Trademark	Copyright/Patent/Trademark	129
Medicare/Medicaid	Medicare/Medicaid	92
Budget/Appropriations	Budget/Appropriations	83
Health Issues	Health Issues	56
Labor Issues/Antitrust/Workplace	Labor Issues/Antitrust/Workplace	43
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	27
Manufacturing	Manufacturing	8
Consumer Issues/Safety/Products	Consumer Issues/Safety/Products	2
Science/Technology	Science/Technology	2
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	2
Transportation	Transportation	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1843119th Congress

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.

Client expense: $770,000 · Firm income: —

Matched citations: H.R.1843

H.R. 3152119th Congress

Patent Eligibility Restoration Act of 2025

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $770,000 · Firm income: —

Matched citations: H.R.3152

H.R. 3160119th Congress

PREVAIL Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $770,000 · Firm income: —

Matched citations: H.R.3160

H.R. 3269119th Congress

ETHIC Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $770,000 · Firm income: —

Matched citations: H.R.3269

Show 21 more cited filings

H.R. 4132119th Congress

Prescription Information Modernization Act of 2025

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.

Client expense: $770,000 · Firm income: —

Matched citations: H.R.4132

H.R. 4191119th Congress

MAPS Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.

Client expense: $770,000 · Firm income: —

Matched citations: H.R.4191

H.R. 5811119th Congress

Restoring America’s Leadership in Innovation Act of 2025

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $770,000 · Firm income: —

Matched citations: H.R.5811

H.R. 6485119th Congress

Skinny Labels, Big Savings Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $770,000 · Firm income: —

Matched citations: H.R.6485

H.R. 8269119th Congress

CLEAR LABELS Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

General Trade Issues. Drug Supply Chain. Rules of Origin. Country of Origin Labeling. Tariffs on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars. India Trade Negotiations. United States-Mexico-Canada Agreement. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act.

Client expense: $770,000 · Firm income: —

Matched citations: H.R.8269

H.R. 8269119th Congress

CLEAR LABELS Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.

Client expense: $770,000 · Firm income: —

Matched citations: H.R.8269

H.R. 9661119th Congress

Expedited Access to Biosimilars Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.

Client expense: $770,000 · Firm income: —

Matched citations: H.R.9661

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $770,000 · Firm income: —

Matched citations: S.1041

S. 1096119th Congress

Preserve Access to Affordable Generics and Biosimilars Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $770,000 · Firm income: —

Matched citations: S.1096

S. 1302119th Congress

Increasing Transparency in Generic Drug Applications Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.

Client expense: $770,000 · Firm income: —

Matched citations: S.1302

S. 1414119th Congress

Expedited Access to Biosimilars Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.

Client expense: $770,000 · Firm income: —

Matched citations: S.1414

S. 1546119th Congress

Patent Eligibility Restoration Act of 2025

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $770,000 · Firm income: —

Matched citations: S.1546

S. 1553119th Congress

PREVAIL Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $770,000 · Firm income: —

Matched citations: S.1553

S. 1784119th Congress

MAPS Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.

Client expense: $770,000 · Firm income: —

Matched citations: S.1784

S. 2027119th Congress

Prescription Information Modernization Act of 2025

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.

Client expense: $770,000 · Firm income: —

Matched citations: S.2027

S. 2276119th Congress

ETHIC Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $770,000 · Firm income: —

Matched citations: S.2276

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.

Client expense: $770,000 · Firm income: —

Matched citations: S.2658

S. 3469119th Congress

BIOSECURE Act of 2025

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.

Client expense: $770,000 · Firm income: —

Matched citations: S.3469

S. 3788119th Congress

CLEAR LABELS Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

General Trade Issues. Drug Supply Chain. Rules of Origin. Country of Origin Labeling. Tariffs on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars. India Trade Negotiations. United States-Mexico-Canada Agreement. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act.

Client expense: $770,000 · Firm income: —

Matched citations: S.3788

S. 3788119th Congress

CLEAR LABELS Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.

Client expense: $770,000 · Firm income: —

Matched citations: S.3788

S. 4280119th Congress

SAFE Act

2026 · third_quarter · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES

Open original LDA filing ↗

Cited source text and reported amounts

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Drug Shortages. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.9661: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Hassan Purple Book Proposal. H.R.8269/S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. American Made Medicines Act. PBM Bid Transparency. S.4280: Security And Freedom Enhancement Act of 2026 (SAFE) Act.

Client expense: $770,000 · Firm income: —

Matched citations: S.4280

Source: Senate LDA